Study Set Content:
For very severe attacks: 0.25-0.5 mg, may be
given IV or IM.
Ergotamine tartrate,
is favored
by some clinicians for treatment of
intractable migraine. Intranasal
dihydroergotamine may also be effective
Dihydroergotamine, 0.5-1 mg IV,
which was used for migraine
prophylaxis in the past, was withdrawn
because of toxicity.
Methysergide,
Increased serum levels of the anterior pituitary
hormone prolactin are associated with secreting
tumors of the gland and also with the use of
centrally acting dopamine antagonists,
especially the D 2-blocking antipsychotic drugs.
Hyperprolactinemia
Because of negative feedback effects,
hyperprolactinemia is associated with
(blank) and (blank) in women as well as
(blank) in both sexes.
amenorrhea, galactorrhea, infertility
Rarely, the prolactin surge that occurs around
the end of term pregnancy may be associated
with
heart failure
Rarely, the prolactin surge that occurs around
the end of term pregnancy may be associated
with heart failure; (blank) has been used to
treat this cardiac condition successfully.
cabergoline
is extremely effective in
reducing the high levels of prolactin that result
from pituitary tumors and has even been
associated with regression of the tumor in some
cases.
Bromocriptine
The usual dosage of bromocriptine is (blank)
2.5 mg, two
or three times daily.
is similar but more potent.
Cabergoline
has also been used in the same
dosage to suppress physiologic lactation.
Bromocriptine
toxicity has been reported in association with the
latter use of
bromocriptine or pergolide.
The (blank) at term is extremely sensitive to the
stimulant action of ergot, and even moderate
doses produce a prolonged and powerful spasm
of the muscle quite unlike natural labor.
uterus
Therefore, ergot derivatives should be used only
for control of (blank) and
should never be given before delivery.
postpartum uterine bleeding
is the preferred agent for control of
postpartum hemorrhage,
Oxytocin
Oxytocin is the preferred agent for control of
postpartum hemorrhage, but if this peptide
agent is ineffective,
ergonovine maleate,
but if this peptide
agent is ineffective, ergonovine maleate, (blank). It is usually effective within (blank) and is less toxic than other ergot
derivatives for this application.
0.2
mg given IM, 1-5
minutes
It is given at the time of delivery of the placenta
or immediately afterward if bleeding is
significant
Ergonovine given(blank)produces
prompt vasoconstriction during coronary
angiography to diagnose variant angina if
reactive segments of the coronary arteries are
present.
intravenously
Ergonovine given intravenously produces
prompt vasoconstriction during coronary
angiography to diagnose variant angina if
reactive segments of the coronary arteries are
present. In Europe, (blank) has been
used for this purpose.
methylergometrine
